[
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts",
    "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=1bc141fa1946d75067a408d2b29f6609606dfd4d3423946cb56669fa0d54422b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753739404,
      "headline": "Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts",
      "id": 136113495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=1bc141fa1946d75067a408d2b29f6609606dfd4d3423946cb56669fa0d54422b"
    }
  },
  {
    "ts": null,
    "headline": "Why Gilead Sciences Stock Slipped Today",
    "summary": "Changes in a federal healthcare authority could negatively impact one of the company's important businesses.",
    "url": "https://finnhub.io/api/news?id=e1466bbcaec17a8e74ed98768e6bead88344b1360623cf726e75ef81e1f2fc1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753734731,
      "headline": "Why Gilead Sciences Stock Slipped Today",
      "id": 136113496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Changes in a federal healthcare authority could negatively impact one of the company's important businesses.",
      "url": "https://finnhub.io/api/news?id=e1466bbcaec17a8e74ed98768e6bead88344b1360623cf726e75ef81e1f2fc1f"
    }
  },
  {
    "ts": null,
    "headline": "Biotech stocks dip as Trump administration mulls patent fee overhaul",
    "summary": "Investing.com -- Biotech stocks fell across the board Monday afternoon, with the SPDR S&P Biotech ETF (NYSE:XBI) dropping to a low of 1.1% after reports emerged that the Trump administration is considering a major overhaul of the U.S. patent system.",
    "url": "https://finnhub.io/api/news?id=62c4a767d17ea9fa389a30852e09a3357654725d5a485cea652900b5d9b1c91a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753733633,
      "headline": "Biotech stocks dip as Trump administration mulls patent fee overhaul",
      "id": 136113491,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Investing.com -- Biotech stocks fell across the board Monday afternoon, with the SPDR S&P Biotech ETF (NYSE:XBI) dropping to a low of 1.1% after reports emerged that the Trump administration is considering a major overhaul of the U.S. patent system.",
      "url": "https://finnhub.io/api/news?id=62c4a767d17ea9fa389a30852e09a3357654725d5a485cea652900b5d9b1c91a"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=437a710cd6599191720bc9448aa7f431c232f3362fd8d38d131b861edf92cbdd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753720620,
      "headline": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
      "id": 136123208,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=437a710cd6599191720bc9448aa7f431c232f3362fd8d38d131b861edf92cbdd"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences stock falls amid reports of preventive health panel dismissal",
    "summary": "Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.8% Monday morning following reports that Health and Human Services Secretary Robert F. Kennedy Jr. plans to dismiss all members of a key advisory panel that influences insurance coverage requirements for preventive medications, including HIV drugs that Gilead produces. The Wall Street Journal reported Friday that Kennedy intends to remove all 16 members of the U.S. Preventive Services Task Force, viewing them as too \"woke,\" according to",
    "url": "https://finnhub.io/api/news?id=0214f7c6f4b6eba7be16772686b0bc8c862f347e849559a628d2b4d54b619ef9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753710882,
      "headline": "Gilead Sciences stock falls amid reports of preventive health panel dismissal",
      "id": 136108335,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.8% Monday morning following reports that Health and Human Services Secretary Robert F. Kennedy Jr. plans to dismiss all members of a key advisory panel that influences insurance coverage requirements for preventive medications, including HIV drugs that Gilead produces. The Wall Street Journal reported Friday that Kennedy intends to remove all 16 members of the U.S. Preventive Services Task Force, viewing them as too \"woke,\" according to",
      "url": "https://finnhub.io/api/news?id=0214f7c6f4b6eba7be16772686b0bc8c862f347e849559a628d2b4d54b619ef9"
    }
  },
  {
    "ts": null,
    "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
    "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
    "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753706498,
      "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
      "id": 136107253,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177313278/image_2177313278.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
      "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2"
    }
  },
  {
    "ts": null,
    "headline": "Gilead wins positive European approval opinion for twice-yearly HIV injection",
    "summary": "The CHMP positive recommendation comes a month after the WHO backed the drug for global HIV prevention.",
    "url": "https://finnhub.io/api/news?id=bb9484c70b35e083fde9e3c43afa2484ac9f49f8846bfc71b64b95c0eb839b74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753700682,
      "headline": "Gilead wins positive European approval opinion for twice-yearly HIV injection",
      "id": 136108336,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The CHMP positive recommendation comes a month after the WHO backed the drug for global HIV prevention.",
      "url": "https://finnhub.io/api/news?id=bb9484c70b35e083fde9e3c43afa2484ac9f49f8846bfc71b64b95c0eb839b74"
    }
  },
  {
    "ts": null,
    "headline": "HCSA Community Services and Tan Tock Seng Hospital Sign MOU to Hepatitis C Elimination in Singapore",
    "summary": "In celebration of the World Hepatitis Day (28 July), HCSA Community Services and Tan Tock Seng Hospital (TTSH), an anchor hospital of NHG Health, today signed a Memorandum of Understanding (MoU) to reinforce their shared commitment to eliminating Hepatitis C (HCV) among former drug offenders in Singapore, the World Health Organization's global strategy of eliminating Hepatitis C.",
    "url": "https://finnhub.io/api/news?id=bb0c22ad4616f2ffe6e4020049cf6c2ab644b1699797d2532e2da7f421263c88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753690260,
      "headline": "HCSA Community Services and Tan Tock Seng Hospital Sign MOU to Hepatitis C Elimination in Singapore",
      "id": 136108337,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "In celebration of the World Hepatitis Day (28 July), HCSA Community Services and Tan Tock Seng Hospital (TTSH), an anchor hospital of NHG Health, today signed a Memorandum of Understanding (MoU) to reinforce their shared commitment to eliminating Hepatitis C (HCV) among former drug offenders in Singapore, the World Health Organization's global strategy of eliminating Hepatitis C.",
      "url": "https://finnhub.io/api/news?id=bb0c22ad4616f2ffe6e4020049cf6c2ab644b1699797d2532e2da7f421263c88"
    }
  },
  {
    "ts": null,
    "headline": "Citi Maintains a Buy Rating on Gilead Sciences (GILD)",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on July 21, Geoff Meacham from Citi maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a price target of $125.00. On July 14, Gilead Sciences, Inc. (NASDAQ:GILD) presented new data on the twice-yearly […]",
    "url": "https://finnhub.io/api/news?id=ebbfca9c78261133fb5939172b51f7c56b96961a11d1b4393bd2a523ad139aed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682892,
      "headline": "Citi Maintains a Buy Rating on Gilead Sciences (GILD)",
      "id": 136108338,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on July 21, Geoff Meacham from Citi maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a price target of $125.00. On July 14, Gilead Sciences, Inc. (NASDAQ:GILD) presented new data on the twice-yearly […]",
      "url": "https://finnhub.io/api/news?id=ebbfca9c78261133fb5939172b51f7c56b96961a11d1b4393bd2a523ad139aed"
    }
  },
  {
    "ts": null,
    "headline": "TD Cowen Remains Bullish on Gilead Sciences (GILD)",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most profitable biotech stocks to invest in now. TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) on July 23, setting a price target of $110.00. Buren based the optimistic rating on the company’s market position and financial projections, increasing the […]",
    "url": "https://finnhub.io/api/news?id=9e8a5493eb84fdb7196b98ed002abf50e23edd71665c7377f959a03f2fb66cee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682852,
      "headline": "TD Cowen Remains Bullish on Gilead Sciences (GILD)",
      "id": 136108339,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most profitable biotech stocks to invest in now. TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) on July 23, setting a price target of $110.00. Buren based the optimistic rating on the company’s market position and financial projections, increasing the […]",
      "url": "https://finnhub.io/api/news?id=9e8a5493eb84fdb7196b98ed002abf50e23edd71665c7377f959a03f2fb66cee"
    }
  }
]